References
- Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.
- National Multiple Sclerosis Society [Internet]. New York (NY): NMSS. Heath policy fact sheet #2: financial burdens for people with MS, their families, and society; 2019 [cited 2019 October 10]. Available from: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Documents/Health-Policy-Fact-Sheet-2-Costs.pdf
- IQVIA Institute for Human Data Science [Internet]. Medicines use and spending in the U.S. A review of 2016 and outlook to 2021; 2017 [cited 2019 October 10]. Available from: https://www.iqvia.com/institute/reports/medicines-use-and-spending-in-the-us-areview-of-2016
- Milliman [Internet]. Report commissioned by Biogen. Multiple sclerosis: new perspectives on the patient journey; 2016 [cited 2019 October 10]. Available from: http://us.milliman.com/uploadedFiles/insight/2016/multiple-sclerosis newperspectives.pdf.
- Optum Rx [Internet]. Six cost drivers of multiple sclerosis; 2019 [cited 2019 October 20]. Available from: https://www.optum.com/resources/library/ms-cost-drivers.html.
- Analysource [Internet]. AnalySource online: premier access to the first Databank drug pricing database. 2019 [cited 2019 January 15]. Available from: https://www.analysource.com
- Centers for Medicare and Medicaid Services [Internet]. Woodlawn (MD): CMS. Physician fee schedule; 2020 [cited 2020 April 06]. Available from: https://www.cms.gov/apps/physician-fee-schedule/
- Ocrevus sample coding [Internet]. Multiple sclerosis; 2019 [cited 2019 October 20]. Available from: https://www.genentechaccess.com/content/dam/gene/accesssolutions/pdfs/coding/OCERVUS-Billing-Coding-for-ALL.pdf
- Ocrevus® highlights of prescribing information [Internet]. 2019 [cited 2019 October 20]. Available from: https://www.gene.com/download/pdf/ocrevus_prescribing.pdf
- Lemtrada® prescribing information, including boxed warning. [cited 2019. October 20]. Available from: https://www.lemtradahcp.com/dosing
- Tysabri® highlights of prescribing information [Internet]. 2019 [cited 2019 October 2019]. Available from: https://www.tysabrihcp.com/content/dam/commercial/tysabri/hcp/en_us/pdf/tysabri_prescribing_information.pdf
- Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. JMCP. 2002;8(6):469–476.
- Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618–625.
- Marrie RA, Patten SB, Tremlett H, et al. Sex differences in comorbidity at diagnosis of multiple sclerosis. A population-based study. Neurology. 2016;86(14):1279–1286.
- Edwards NC, Munsell M, Menzin J, et al. Comorbidity in US patients with multiple sclerosis. PROM. 2018;9:97–102.
- O’Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ. 2011;14(5):617–627.
- Beckerman R, Aragão F, Duff S, et al. Four-year resource use and costs associated with administration and monitoring of disease modifying drugs in patients with relapsing multiple sclerosis. Paper presented at: International Society for Pharmocoeconomics and Outcomes Research Europe (ISPOR EU); 2018 November 10–14; Barcelona, Spain.
- Institute for Clinical and Economic Review [Internet]. Boston (MA): ICER. Disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis: effectiveness and value. Final Evidence Report; 2017 [cited 2019 October 20]. Available from: https://icer-review.org/wpcontent/uploads/2016/08/CTAF_MS_Final_Report_030617.pdf
- Yang H, Duchesneau E, Foster R, et al. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. J Med Econ. 2017;20(10):1056–1065.
- Alimohamadi S, Vollmer B, Nair K, et al. Ocrelizumab safety and effectiveness in the one year treatment of multiple sclerosis compared to other disease modifying therapies. Neurology. 2019;92(15):P3.2.
- Kruse GB, Amonkar MM, Smith G, et al. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. JMCP. 2008;14(9):844–857.
- Skarin AT, Duh MS, Weiner JR, et al. Costs associated with intravenous (IV) chemotherapy administration in patients with lung cancer. JCO. 2007;25(18):18092–18092.
- Wong BJ, Cifaldi MA, Roy S, et al. Analysis of drug and administrative costs allowed by U.S. private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis. JMCP. 2011;17(4):313–320.
- Schmier J, Ogden K, Nickman N, et al. Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting. Clin Ther. 2017;39(8):1600–1617.
- Dieguez G, Engel T, Jacobson N. Site of service and cost dispersion of infused drugs. Seattle (WA): Milliman; 2019. (Milliman white paper).